Feb 5
A panel of experts from inside several major pharma companies discussed regulatory initiatives around pragmatic trials in depth at the recent Summit for Clinical Trial Ops Executives (SCOPE). “I got a fever and the only prescription is more pragmatic trials,” quipped Henry Wei, M.D., head of development innovation at Regeneron and a major fan of TransCelerate’s recent “tabletop exercise” with the U.S. Food and Drug Administration (FDA) as well as the agency’s CDER Center for Clinical Trial Innovation (C3TI) demonstration project focused on the topic.
Read the full article from Clinical Research News here.
Related Blog Posts
Expanding clinical trial access through technology, support
Clinical trials are a key tool for producing the safety and efficacy data that guide new therapies to market. Progress in clinical research relies on those who volunteer to participate, and yet, access to trials is not the same for everyone in the United States. Read the full article featuring Allison Cuff Shimooka from TechTarget…
Good Clinical Practice has Changed: Are You Ready for ICH-E6(R3)?
ICH-E6(R3) represents a shift in mindset when it comes to clinical trials. Rather than trying to control every part of a trial equally, the guideline wants researchers to focus most on factors that are critical to participant safety and the reliability of trial results. It introduces the idea of “proportionality,” meaning more control is applied…
Seriously … Are We Making Any Progress?
Getz, the Executive Director at the Tufts Center for the Study of Drug Development (CSDD), presented findings from a study they did with TransCelerate BioPharma, which sheds light on the volume and purpose of data collected in clinical trial protocols. His talk centered on a fundamental paradox in modern clinical research: While we have an…